#081 · Drug of the Day Pineal tryptamine MT1 / MT2 agonist OTC (US) · Rx analog ramelteon 2026-09-08

Melatonin

A hormone, not a benzo in a gummy

N-acetyl-5-methoxytryptamine · C13H16N2O2 · MW 232.28 g/mol · CAS 73-31-4 · pineal neurohormone · ChEMBL CHEMBL45

Melatonin. The darkness hormone: pineal N-acetyl-5-methoxytryptamine acting at MT1 and MT2 GPCRs to drop core temperature, gate sleep onset (MT1) and shift circadian phase (MT2). It is not a GABAA hypnotic, not zolpidem #035, and not harmless candy just because the US sells it next to vitamin C. Prescription analog: ramelteon. Structural stand-in: PDB 6ME3 (MT1 + 2-phenylmelatonin).

Primary targetMT1 / MT2
MechanismGi GPCR agonist
MT1 Kisub-nM – low-nM
T½~30 – 60 min
GABAANo
Best usePhase-shift / jet lag
US OTCUnregulated dose/purity
01 · Mechanism of Action

Two Receptors, One Clock, No Chloride Channel

MT1 (sleep onset, SCN suppression of neuronal firing, Gi) and MT2 (phase-shifting the clock) are GPCRs, not ion channels. Melatonin is made from serotonin via arylalkylamine N-acetyltransferase (the night enzyme) plus HIOMT. Light at night shuts this off — which is the whole modern-lighting problem.

Exogenous melatonin is a phase-shifting tool more than a knock-out hypnotic. Timing relative to DLMO matters; taking 10 mg 'to pass out' is using a hormone as a blunt object. Ramelteon is the MT1/MT2 agonist with pharmacokinetics a regulator actually reviewed. US gummies have been assayed at a fraction of — or many times — the labeled dose.

① MT1

Gi-coupled; SCN and sleep-onset. Sub-nM agonist. The 'I'm getting sleepy' arm.

② MT2

Phase shift. This is why 0.5 mg at the right clock time can beat 10 mg at the wrong one.

③ Not GABA-A

No benzo pocket, no Z-drug complex sleep-driving, no flumazenil. Also no opioid.

④ Metabolism

CYP1A2 (major) to 6-hydroxymelatonin, then sulfate. Fluvoxamine (1A2 inhibitor) can massively raise levels.

⑤ OTC chaos (US)

Dietary-supplement loophole: labeled 3 mg may be 0.1 or 9. Label is not a PK study.

⑥ Kids / neurodev

Pediatric gummy culture is ahead of the evidence. Endogenous puberty/circadian questions are not settled by marketing.

Darkness → pineal AANAT → melatonin → MT1/MT2 → sleep gate / phase
Wrong-time megadose → next-day fog, phase noise → not a substitute for CBT-I or a hypnotic plan
02 · Pharmacokinetics

A Hormone With a Half-Life of Minutes

Oral bioavailability is low and first-pass heavy. Tmax ~30–60 min; t½ ~30–60 min for immediate-release. Sustained-release tries to mimic the nocturnal profile and often just smears the next morning.

Endogenous peakmid-dark (DLMO +)
Exogenous Tmax~30 – 60 min
T½ (IR)~30 – 60 min
Bioavailabilitylow, first-pass
CYP1A2 (major)
Fluvoxamine↑↑ levels
OTC (US)unregulated assay
Rx analogramelteon
03 · Jet Lag Versus Insomnia

Clock Tool, Not Ambien Jr.

Evidence is strongest for circadian indications (jet lag, delayed sleep phase) at low milligram doses timed to the clock. Primary insomnia is a weaker story, and high-dose sedation is hangover plus prolactin/temperature noise. If you need a hypnotic, that is a different receptor page (zolpidem #035) with a different harm profile — not a reason to 20 mg the gummy.

04 · FlexAIDΔS · Shannon Entropy Analysis

A Compact Tryptamine in a Sealed Pocket

FlexAIDΔS · Entropy Commentary

PDB 6ME3 is MT1 with 2-phenylmelatonin, not the endogenous ligand — honestly labeled. The pocket is sealed from solvent by ECL2; ligand entry is thought to be via a lipid-facing channel. Aromatic stack on Phe179 plus H-bonds to Asn162/Gln181. Tiny ligand, tiny ΔS_conf, high affinity: classic pre-organized hormone pose.

05 · Harm Reduction

Mostly Forgiving — Except Dose, Kids, and 1A2

Not a respiratory depressant. The harms are phase errors, next-day fog, unregulated products, and CYP1A2 traps.

Not a hypnotic license

  • Will not reverse insomnia the way a Z-drug does — and that is good
  • High doses → next-day grogginess, vivid dreams, temperature drop

Product quality (US OTC)

  • Assays disagree with labels; melatonin was found in some 'melatonin-free' products and vice versa
  • Prefer USP-verified or prescription ramelteon if you need a known dose

Interactions

  • Fluvoxamine (CYP1A2) can multiply exposure
  • Anticoagulant case reports — monitor if high-dose chronic

Practice

  • Low dose (0.3–1 mg) timed to DLMO often beats 10 mg at bedtime
  • Pediatric routine use is a cultural experiment
NOT a respiratory-kill combination drug at ordinary doses — do not stack that fact into 'safe with opioids/benzos' as if it were a reason those remain safe. The serious melatonin-specific harms are unregulated pediatric dosing and CYP1A2 inhibition (fluvoxamine).
3D · Human MT1 + 2-phenylmelatonin analog PDB: 6ME3
Loading structure from RCSB…
Receptor (refined cartoon)
Contact residues
Ligand (ball-and-stick)
Structure: 6ME3 — XFEL MT1 + 2-phenylmelatonin (Stauch et al., Nature 2019). Analog, not endogenous melatonin — same pocket, honestly labeled. 6ME2 is ramelteon in the same receptor. Rotate · scroll to zoom · right-drag to translate.
View on RCSB →

Receptor Binding Affinities

melatonin receptors
Target Affinity Rel. Action
MT1
melatonin receptor 1A
Ki sub-nM – low-nM
Gi agonist
Agonist
MT2
melatonin receptor 1B
Ki sub-nM – low-nM
phase shift
Agonist
5-HT receptors
serotonin GPCRs
weak / none at Rx
despite tryptamine scaffold
Negligible
GABAA
hypnotic site
none
not a Z-drug
None
Melatonin MT1/MT2 affinities are sub- to low-nanomolar (ChEMBL CHEMBL45). PDB 6ME3 is 2-phenylmelatonin, an analog in the same MT1 pocket.